Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1986 1
1987 1
1988 4
1989 2
1990 4
1991 2
1992 2
1993 3
1994 7
1995 5
1996 2
1997 1
1998 2
1999 1
2000 1
2001 3
2002 2
2003 2
2004 3
2005 2
2006 1
2009 2
2010 3
2011 3
2012 2
2013 4
2014 3
2015 6
2016 4
2017 4
2018 2
2019 1
2020 3
2021 2
2022 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Results by year

Filters applied: . Clear all
Page 1
CDK7 inhibitors as anticancer drugs.
Sava GP, Fan H, Coombes RC, Buluwela L, Ali S. Sava GP, et al. Among authors: buluwela l. Cancer Metastasis Rev. 2020 Sep;39(3):805-823. doi: 10.1007/s10555-020-09885-8. Cancer Metastasis Rev. 2020. PMID: 32385714 Free PMC article. Review.
ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation.
Li Z, McGinn O, Wu Y, Bahreini A, Priedigkeit NM, Ding K, Onkar S, Lampenfeld C, Sartorius CA, Miller L, Rosenzweig M, Cohen O, Wagle N, Richer JK, Muller WJ, Buluwela L, Ali S, Bruno TC, Vignali DAA, Fang Y, Zhu L, Tseng GC, Gertz J, Atkinson JM, Lee AV, Oesterreich S. Li Z, et al. Among authors: buluwela l. Nat Commun. 2022 Apr 19;13(1):2011. doi: 10.1038/s41467-022-29498-9. Nat Commun. 2022. PMID: 35440136 Free PMC article.
Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis.
Li Z, Wu Y, Yates ME, Tasdemir N, Bahreini A, Chen J, Levine KM, Priedigkeit NM, Nasrazadani A, Ali S, Buluwela L, Arnesen S, Gertz J, Richer JK, Troness B, El-Ashry D, Zhang Q, Gerratana L, Zhang Y, Cristofanilli M, Montanez MA, Sundd P, Wallace CT, Watkins SC, Fumagalli C, Guerini-Rocco E, Zhu L, Tseng GC, Wagle N, Carroll JS, Jank P, Denkert C, Karsten MM, Blohmer JU, Park BH, Lucas PC, Atkinson JM, Lee AV, Oesterreich S. Li Z, et al. Among authors: buluwela l. Cancer Res. 2022 Apr 1;82(7):1321-1339. doi: 10.1158/0008-5472.CAN-21-2576. Cancer Res. 2022. PMID: 35078818 Free PMC article.
Estrogen receptors and anti-estrogen therapies.
Buluwela L, Constantinidou D, Pike J, Ali S. Buluwela L, et al. Cancer Treat Res. 2004;119:271-92. doi: 10.1007/1-4020-7847-1_13. Cancer Treat Res. 2004. PMID: 15164882 Review. No abstract available.
A complete map of the human immunoglobulin VH locus.
Tomlinson IM, Cook GP, Walter G, Carter NP, Riethman H, Buluwela L, Rabbitts TH, Winter G. Tomlinson IM, et al. Among authors: buluwela l. Ann N Y Acad Sci. 1995 Sep 29;764:43-6. doi: 10.1111/j.1749-6632.1995.tb55804.x. Ann N Y Acad Sci. 1995. PMID: 7486559 Review. No abstract available.
Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer.
Harrod A, Lai CF, Goldsbrough I, Simmons GM, Oppermans N, Santos DB, Győrffy B, Allsopp RC, Toghill BJ, Balachandran K, Lawson M, Morrow CJ, Surakala M, Carnevalli LS, Zhang P, Guttery DS, Shaw JA, Coombes RC, Buluwela L, Ali S. Harrod A, et al. Among authors: buluwela l. Oncogene. 2022 Oct;41(44):4905-4915. doi: 10.1038/s41388-022-02483-8. Epub 2022 Oct 5. Oncogene. 2022. PMID: 36198774 Free PMC article.
88 results